Acupuncture Reduces Frequency of Chronic Tension-Type Headaches
Responder rate higher with true acupuncture (needling to achieve deqi sensation) versus superficial acupuncture (sham control)
Responder rate higher with true acupuncture (needling to achieve deqi sensation) versus superficial acupuncture (sham control)
Memory impairment and decreased concentration most prevalent symptoms at six-month follow-up
Compared with placebo, increase in responder rates seen at all atogepant dose levels
Decrease seen in median pain rating from baseline to end of hospitalization; pain rating remained below baseline at postdischarge visit
The NDA submission includes data from 2 pivotal studies that evaluated zavegepant in adults with at least a 1-year history of migraine and migraine attacks.
Series of case reports shows some success with Paxlovid in treating patients with long COVID
AXS-07 is an oral agent that consists of meloxicam, a COX-2 preferential nonsteroidal anti-inflammatory drug, and rizatriptan, a 5-HT1B/1D agonist.
Active stimulation with tDCS can reduce the number of migraine days per month, pain intensity
Rimegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist.
The PROGRESS study compared the efficacy and safety of atogepant to placebo in 778 adults with at least a 1-year history of chronic migraine.